SynthesisFrontiers in oncology2026
Evolution and recent advances in antibody-drug conjugate therapy for lung cancer: a comprehensive systematic review based on the Trialtrove database (inception to July 1, 2025).
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-drug conjugates (ADCs) are emerging targeted therapies in cancer treatment. They selectively deliver cytotoxic payloads to tumor cells, improving efficacy and reducing toxicity. However, the clinical trial landscape in lung cancer remains unclear. This systematic review analyzes registered ADC trials in lung cancer comprehensively. Methods: Trials were retrieved from the Trialtrove database from inception to July 1, 2025, focusing on ADC interventions in lung cancer. The inclusion criteria required complete ADC data, excluding observational studies or incomplete records. The analyses covered trial numbers, geography, funding, phases, design, targets, linkers, payloads, and biomarkers. This review follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: A total of 546 global trials were identified, of which 466 were included. The trial registrations grew exponentially from one in 2001 to 106 in 2024. Most trials were single-continent and industry-funded. Early phases predominated. A total of 76 targets were involved, with the top 15 (e.g., trophoblast cell surface antigen 2 (TROP2), 18.07%; human epidermal growth factor receptor 2 (HER2), 17.65%) accounting for 78.15%. The linkers were mainly cleavable protease-dependent. Payloads were dominated by DNA topoisomerase I inhibitors. Biomarkers were featured in 85.84% of trials. Conclusion: This review highlights the rapid expansion and regional focus of ADC trials in lung cancer, driven by early phases and industry support. Diverse targets emphasize TROP2 and HER2, while biomarkers advance precision medicine from standard testing to personalized regimens. Novel targets and combinations enhance selectivity. Optimized linkers mitigate off-target risks, such as the risk of interstitial lung disease (ILD). This analysis offers researchers comprehensive insights and advocates for strengthened intercontinental collaboration and late-phase trials to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.